Similarly, co-targeting fibroblast activation protein (FAP) and prostate stem cell antigen (PSCA) with dual-antigen CAR-T cells has been shown to enhance tumor clearance while reducing the risk of antigen escape 103. Here, FAP is linked to neoplasm.